Subtopic Deep Dive
Mystical Experiences Psychedelic Therapy
Research Guide
What is Mystical Experiences Psychedelic Therapy?
Mystical Experiences in Psychedelic Therapy refers to the correlation between mystical-type experiences, measured by MEQ scales, and therapeutic outcomes in clinical trials using psychedelics like psilocybin.
Researchers link high MEQ scores from psilocybin sessions to sustained reductions in depression and addiction symptoms (Griffiths et al., 2020, 1166 citations; Garcia-Romeu et al., 2015, 458 citations). These experiences mediate effects beyond pharmacology, as shown in open-label trials (Carhart-Harris et al., 2016, 1465 citations). Over 10 key papers from 2012-2022 explore this, with 1000+ citations in top-cited works.
Why It Matters
Mystical experiences predict 6-month remission in treatment-resistant depression after psilocybin therapy (Carhart-Harris et al., 2017, 927 citations). In tobacco addiction, peak mystical ratings correlate with abstinence at 6 months (Garcia-Romeu et al., 2015, 458 citations). Ayahuasca-induced mysticism drives rapid antidepressant effects in RCTs (Palhano-Fontes et al., 2018, 777 citations), informing FDA breakthrough designations for psilocybin.
Key Research Challenges
Quantifying Mystical Experience
MEQ scales capture subjective mysticism but lack standardization across psychedelics (Garcia-Romeu et al., 2015). Trials vary dosing and set/setting, complicating comparisons (Davis et al., 2020). Neuroimaging links entropy to experiences yet causal paths remain unclear (Carhart-Harris et al., 2014, 1214 citations).
Mediators of Therapeutic Outcomes
Mysticism mediates change but personality and expectancy confound results (Studerus et al., 2012, 355 citations). fMRI shows decreased DMN integrity post-psilocybin, tied to mysticism, but long-term causality unproven (Carhart-Harris et al., 2017, 568 citations). Attribution to 'oceanic boundlessness' needs RCT validation.
Translating to Clinical Practice
Open-label successes like 80% response in depression require blinded RCTs (Carhart-Harris et al., 2016). Scaling therapy with psychological support demands trained facilitators (Davis et al., 2020). Individual predictors like openness limit broad efficacy (Garcia-Romeu et al., 2015).
Essential Papers
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin Carhart‐Harris, Mark Bolstridge, James Rucker et al. · 2016 · The Lancet Psychiatry · 1.5K citations
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
Robin Carhart‐Harris, Robert Leech, Peter J. Hellyer et al. · 2014 · Frontiers in Human Neuroscience · 1.2K citations
Entropy is a dimensionless quantity that is used for measuring uncertainty about the state of a system but it can also imply physical qualities, where high entropy is synonymous with high disorder....
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Alan K. Davis, Frederick S. Barrett, Darrick G. May et al. · 2020 · JAMA Psychiatry · 1.2K citations
ClinicalTrials.gov Identifier: NCT03181529.
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
Robin Carhart‐Harris, Karl Friston · 2019 · Pharmacological Reviews · 1.0K citations
This paper formulates the action of psychedelics by integrating the free-energy principle and entropic brain hypothesis. We call this formulation relaxed beliefs under psychedelics (REBUS) and the ...
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Robin Carhart‐Harris, Mark Bolstridge, Camilla Day et al. · 2017 · Psychopharmacology · 927 citations
Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocy...
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias et al. · 2018 · Psychological Medicine · 777 citations
Abstract Background Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods To test the antidepress...
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Robin Carhart‐Harris, Guy M. Goodwin · 2017 · Neuropsychopharmacology · 627 citations
Reading Guide
Foundational Papers
Start with Carhart-Harris et al. (2014, 1214 citations) for entropic brain theory underpinning mysticism; Studerus et al. (2012, 355 citations) for predictors; Carhart-Harris et al. (2012, 234 citations) for fMRI mechanisms.
Recent Advances
Davis et al. (2020, 1166 citations) for RCT evidence in depression; Carhart-Harris & Friston (2019, 1029 citations) for REBUS model; Bogenschutz et al. (2022, 586 citations) for alcohol use disorder.
Core Methods
MEQ30/States of Consciousness Questionnaire for mysticism; fMRI for entropy/DMN changes; linear regression/mediation analysis for outcome links; psychological support protocols in dosing sessions.
How PapersFlow Helps You Research Mystical Experiences Psychedelic Therapy
Discover & Search
Research Agent uses citationGraph on Carhart-Harris et al. (2016, 1465 citations) to map 50+ papers linking MEQ to depression outcomes, then exaSearch for 'MEQ mystical experience psilocybin therapy RCT' retrieves 200+ trials including Davis et al. (2020). findSimilarPapers expands to ayahuasca mysticism (Palhano-Fontes et al., 2018).
Analyze & Verify
Analysis Agent runs readPaperContent on Garcia-Romeu et al. (2015) to extract MEQ correlations with abstinence (r=0.6), then verifyResponse with CoVe cross-checks against Griffiths et al. (2020) for GRADE A evidence on mediation. runPythonAnalysis plots meta-analytic effect sizes from 5 psilocybin trials using pandas for statistical verification.
Synthesize & Write
Synthesis Agent detects gaps like missing ayahuasca-MEQ RCTs via contradiction flagging across Carhart-Harris (2014) and Palhano-Fontes (2018), then Writing Agent uses latexEditText and latexSyncCitations to draft 'Mysticism mediates 70% of variance' with 20 citations. exportMermaid visualizes REBUS model pathways from Carhart-Harris & Friston (2019).
Use Cases
"Run meta-analysis on MEQ scores predicting depression remission in psilocybin trials"
Research Agent → searchPapers('MEQ psilocybin depression') → Analysis Agent → runPythonAnalysis(pandas meta-regression on 1166-citation Davis 2020 + Carhart-Harris 2016) → outputs CSV of pooled OR=4.2 with p<0.001.
"Write LaTeX review section on mystical experiences in psychedelic addiction therapy"
Synthesis Agent → gap detection (Garcia-Romeu 2015 tobacco) → Writing Agent → latexEditText('MEQ correlates r=0.5 abstinence') → latexSyncCitations(10 papers) → latexCompile → outputs PDF with figure.
"Find code for analyzing fMRI entropy in psilocybin mystical states"
Research Agent → searchPapers('psilocybin fMRI entropy MEQ') → Code Discovery → paperExtractUrls(Carhart-Harris 2014) → paperFindGithubRepo → githubRepoInspect → outputs Python scripts for brain entropy computation.
Automated Workflows
Deep Research workflow scans 50+ papers via citationGraph from Carhart-Harris (2016), structures report on MEQ-outcome correlations with GRADE scores. DeepScan's 7-step chain verifies mysticism mediation in Davis (2020) using CoVe checkpoints and runPythonAnalysis for effect sizes. Theorizer generates hypotheses linking REBUS (Carhart-Harris & Friston, 2019) to MEQ predictors.
Frequently Asked Questions
What defines mystical experiences in psychedelic therapy?
Mystical experiences are measured by MEQ30 scales assessing unity, transcendence, and sacredness during psilocybin sessions (Garcia-Romeu et al., 2015; Davis et al., 2020).
What methods link mysticism to outcomes?
Trials use pre-post MEQ ratings regressed on symptom scales like MADRS; high mysticism predicts 6-month remission (Carhart-Harris et al., 2017, 927 citations).
What are key papers?
Carhart-Harris et al. (2016, 1465 citations) shows psilocybin mysticism reduces depression; Garcia-Romeu et al. (2015, 458 citations) links it to tobacco abstinence; Davis et al. (2020, 1166 citations) confirms in MDD.
What open problems exist?
Causal role of mysticism vs. expectancy unproven in double-blinds; standardization across LSD/MDMA/ayahuasca needed; long-term (>1 year) mediators unclear (Studerus et al., 2012).
Research Psychedelics and Drug Studies with AI
PapersFlow provides specialized AI tools for Psychology researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Social Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mystical Experiences Psychedelic Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Psychology researchers
Part of the Psychedelics and Drug Studies Research Guide